Hong Kong Skyline
Nicada | E+ | Getty Images
Regencell Bioscience Holdings, the latest speculative foreign stock to attract an extraordinary surge in trading demand as early stage Hong Kong-based Bioscience Company is not making any revenue.
Regencell’s shares say on Monday it is developing traditional Chinese herbal treatments to treat childhood attention deficit hyperactivity disorder and autism. The 38-1 split, declared on June 2, came into effect Monday.
According to S&P Capital IQ, the company’s annual performance rose 46,000% in 2025, and 46,000% in Regencell, which was founded in 2014 and traded on Nasdaq under the ticker “RGC” since 2021.
According to FactSet data, Regencell CEO Yat-Gai Au controls 86.24% of the total number of shares outstanding.
Stock chart icon Stock chart icon
Recencell Bioscience Holdings in 2025.
Regencell is the latest example of speculative international stocks that are attracting attention during summer trading. For example, in August 2022, Hong Kong-based fintech company AMTD Digital rose 126%, temporarily giving it a greater market value than Coca-Cola and Bank of America.
Regencell’s market value is roughly equivalent to the Lululemon and Tops Super Micro Computer and the fifth third-bancorp traded by Nasdaq.
Earlier this month, Regencell described a stock split that was designed solely to “enhance liquidity in the market for the company’s common stock and make it more accessible to investors.” A stock split changes nothing fundamentally about the company.
The Regencell surge came into the spotlight even after Robert F. Kennedy Jr. was sworn in February as U.S. Department of Health and Human Services secretary, and focused on alternative medicines. Kennedy, a vaccine skeptic, took steps last week to discourage the U.S. from routine immunizations and removed all members of the panel advising the Centers for Disease Control and Prevention for Vaccines.
Regencell stocks often make huge swings for the day. For example, the stock rose about 30% on March 21, then fell 30% on the next trading day.
Unclear treatment, zero profit
Despite wild spikes in stock, little is known about the effectiveness and commercialization of Legensel’s treatment for ADHD and autism spectrum disorders.
Regencell’s business focuses on its own traditional Chinese herbal medicine (TCM), developed in partnership with TCM practitioner Sik-kee Au, using “Sik-kee au tcm brain theory.” Sik-Kee Au is the father of Regencell CEO Yat-Gai Au, the company said in a 2022 statement.
The three liquid-based oral TCM formula candidates deal with mild, moderate and severe conditions and claim to contain only natural ingredients such as so-called “detoxifying herbs,” blood circulation herbs and digestive herbs.
“These TCM formulas form the basis for TCM product candidates, which we intend to develop and commercialize for the treatment of ADHD and ASD,” reads the Regencell website.
In his latest annual report, filed last October, Regencell said he also submitted TCM-style regulatory approval. For the fiscal years ended June 2024 and 2023, Regencell incurred total losses of $4.36 million and $6.06 million, respectively, according to the filing of 20F with the SEC.
Read the submissions: “You may not generate revenue from TCM Formula candidates, apply for regulatory approval, or receive distribution capabilities or experience, or granted or pending patent applications and may not be beneficial.”
Regencell has not responded to CNBC requests for comments.
Regencell’s latest patient case study dated November 15, 2023 said 28 patients were treated for three months in their second efficacy trial, showing improvements in ADHD and ASD symptoms, according to the company’s website.
In previous cases, Regencell said in a 2021 news release that it used the AU’s revised, unique cold and flu TCM formula to treat suspected or confirmed COVID-19 cases. According to the statement, what was called the improvements in Covid terms was that in September 2021, it formed a joint venture with Honor Epic Enterprises Limited, and established a joint venture with Honor Epic Enterprises Limited to commercialize the company’s Covid handling in ASEAN countries.
Online buzz
The stock has attracted mostly chatter on social media over the past few years. These comments made suggest both retailer enthusiasm and skepticism.
One user on Reddit page “R/ShortSqueeze” wrote on Monday that Regencell “trades like Meme Coin.” Another user said in a post made three months ago, “I take my scalp every day to make a little profit from RGC.” The stock price jumped 1,360% in May alone.
On LinkedIn in May, an investor said, “I can’t stop laughing,” after reading the company’s description. According to his profile, another post from a user in the pharmaceutical industry said last week that Regencell became “stock to see” after a spike in “no official news or catalysts.” Another LinkedIn user commented on Regencell last month, saying, “China-based, low volume and no official news, Bizarro.”
On X, one user wrote in a Monday post that “In the case of #completebullsh___companyoftheyear, we’ll nominate Regencell.”
– CNBC’s Scott Schnipper contributed the report.
